Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InModeSTU:154 +0.99%91 FCF Margin % is 21.80% as of Jun. 2026, which is 40% below its 10-year median of 36.45. GuruFocus rates STU:154 with a GF Score™ of 91/100 and a GF Value™ of €16.98 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 814 Medical Devices & Instruments companies, InMode ranks better than 92.75% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InMode's Free Cash Flow for the
three
months ended in Jun. 2026 was €18.1 Mil. InMode's Revenue for the
three
months ended in Jun. 2026 was €83.0 Mil. Therefore, InMode's FCF Margin % for the quarter that ended in Jun. 2026 was 21.80%.
The historical rank and industry rank for InMode's FCF Margin % or its related term are showing as below:
STU:154'
s FCF Margin % Range Over the Past 10 Years
Min: 22.02 Med: 36.45 Max: 48.65
Current: 22.02
During the past 9 years, the highest FCF Margin % of InMode was 48.65%. The lowest was 22.02%. And the median was 36.45%.
STU:154's FCF Margin % is ranked better than 92.75% of 814
companies
in the Medical Devices & Instruments industry
Industry Median: -0.815
vs STU:154: 22.02
The historical data trend for InMode's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:154 vs BVS, PRCT, AVR: FCF Margin % Comparison
For the Medical Devices subindustry, InMode's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMode FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InMode's FCF Margin % distribution charts can be found below:
* The bar in red indicates where InMode's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMode (STU:154) has a FCF Margin % of 21.80% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InMode and its competitors. This is 40% below median its historical median of 36.45. Over the past decade, InMode's FCF Margin % has ranged from 22.02 to 48.65. According to the industry distribution chart, InMode ranks #59 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 7.2%.
Is InMode's FCF Margin % too high?
InMode's current FCF Margin % of 21.80% is 40% below median its 10-year median of 36.45. Over the past 10 years, this metric has ranged from a low of 22.02 to a high of 48.65. Based on the distribution chart, InMode ranks #59 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InMode has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InMode's FCF Margin % compare to BVS and PRCT?
According to the Medical Devices & Instruments industry distribution chart, InMode ranks #59 out of 814 companies for FCF Margin %. This places InMode in the top 7% of its industry — outperforming the majority of peers. Historically, InMode's own FCF Margin % has ranged from 22.02 to 48.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InMode and its competitors. InMode's current FCF Margin % is 21.80%, which is 40% below median its own 10-year median of 36.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMode stock overvalued right now?
Based on GuruFocus' analysis, InMode (STU:154) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.98, compared to a current price of €13.23 — trading 22.1% below its estimated fair value. The current FCF Margin % is 21.80%, which is 40% below median its 10-year median of 36.45. InMode's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For InMode (STU:154), the current FCF Margin % is 21.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMode (STU:154) Overvalued in 2026?
Based on GuruFocus' analysis, InMode stock appears to be undervalued.
The current stock price of €13.23 is trading 22.1% below its estimated GF Value™ of €16.98.
GuruFocus considers InMode to be Modestly Undervalued.
Key valuation signals for STU:154:
FCF Margin %: 21.80% (40% below median its 10-year median of 36.45)
GF Value™: €16.98 vs. price of €13.23 (22.1% below fair value)
No single metric tells the full story. See the STU:154 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
91GF Score
Get the complete analysis for STU:154
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:154 has been successfully added to your 
